Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (831-840 of 903) with videos related to

Pageof 91
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Blood|March 7, 2015
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformationLapo Alinari, Kiran V Mahasenan, Fengting Yan, et al.
Frontiers in Oncology|July 29, 2022
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic LeukemiaMatthew Kaufman, Xiao-Jie Yan, Wentian Li, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Cancer Cell|April 14, 2010
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemiaShujun Liu, Lai-Chu Wu, Jiuxia Pang, et al.
Haematologica|October 15, 2020
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphomaYoussef Youssef, Vrajesh Karkhanis, Wing Keung Chan, et al.
Journal of Hematology & Oncology|January 16, 2021
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemiaJanek S Walker, Zachary A Hing, Bonnie Harrington, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Pageof 91

Showing results (831-840 of 903) with videos related to

Sort By:
Pageof 91
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Blood|March 7, 2015
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformationLapo Alinari, Kiran V Mahasenan, Fengting Yan, et al.
Frontiers in Oncology|July 29, 2022
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic LeukemiaMatthew Kaufman, Xiao-Jie Yan, Wentian Li, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Cancer Cell|April 14, 2010
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemiaShujun Liu, Lai-Chu Wu, Jiuxia Pang, et al.
Haematologica|October 15, 2020
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphomaYoussef Youssef, Vrajesh Karkhanis, Wing Keung Chan, et al.
Journal of Hematology & Oncology|January 16, 2021
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemiaJanek S Walker, Zachary A Hing, Bonnie Harrington, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Pageof 91